Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5YK | ISIN: US57055L2060 | Ticker-Symbol: GX1
Frankfurt
27.06.25 | 08:05
1,100 Euro
-2,65 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MARKER THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MARKER THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MARKER THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma3
17.06.Marker Therapeutics, Inc. - 8-K, Current Report2
09.06.Marker Therapeutics, Inc. - 8-K, Current Report3
MARKER THERAPEUTICS Aktie jetzt für 0€ handeln
20.05.Marker Therapeutics, Inc. - 8-K, Current Report4
20.05.Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma107Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive...
► Artikel lesen
19.05.Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies6
15.05.Marker Therapeutics, Inc. - 10-Q, Quarterly Report3
31.03.Marker Therapeutics GAAP EPS of -$1.19, revenue of $6.59M14
31.03.Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results142Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses...
► Artikel lesen
31.03.Marker Therapeutics, Inc. - 10-K, Annual Report2
27.03.Marker Therapeutics, Inc. - 8-K, Current Report4
19.02.Marker Therapeutics, Inc. - 8-K, Current Report3
11.02.Brookline Capital sets $4 target on Marker Therapeutics stock10
19.12.24Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma164APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well...
► Artikel lesen
14.11.24Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates204HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
► Artikel lesen
14.08.24Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates131Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
► Artikel lesen
12.08.24Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma159HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1